menu
    • menu

    Company profile for Nicox SA

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Nicox’s portfolio includes three programs in development, all of which are in, or preparing to enter, Phase 2 clinical studies: NCX 470 for reduction of intraocular pressure (IOP) in patients with open angle glaucoma or ocular hypertension; NCX 4251 for patients with acute exacerbations of blepharitis; and NCX 4280 (formerly AC-120) for relief of ocular redness and lid swelling due to morning ocular congestion. NCX 470 is ba...
    Nicox’s portfolio includes three programs in development, all of which are in, or preparing to enter, Phase 2 clinical studies: NCX 470 for reduction of intraocular pressure (IOP) in patients with open angle glaucoma or ocular hypertension; NCX 4251 for patients with acute exacerbations of blepharitis; and NCX 4280 (formerly AC-120) for relief of ocular redness and lid swelling due to morning ocular congestion. NCX 470 is based on our proprietary nitric oxide (NO) donating research platform. NCX 4251 and NCX 4280 are product candidates based on repurposed molecules that have previously been used in other indications and therapeutic areas.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Nicox SAFrance Flag
    Country
    Country
    France
    Address
    Address
    Drakkar 2 - Bld D 2405 road Dolines - CS 10313 Sophia Antipolis
    Telephone
    Telephone
    +33 (0) 4 97 24 53 00
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.nicox.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Nicox Provides First Half 2025 Financial Results
    Nicox Provides First Half 2025 Financial Results

    23 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/23/3171674/0/en/Nicox-Provides-First-Half-2025-Financial-Results.html

    GLOBENEWSWIRE
    23 Oct 2025
    Share Share
    Nicox’s NCX 470 Shows 12-Month Efficacy in Denali Trial
    Nicox’s NCX 470 Shows 12-Month Efficacy in Denali Trial

    02 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/02/3160086/0/en/Nicox-s-NCX-470-Demonstrates-Sustained-Efficacy-through-12-Months-in-Denali-Clinical-Trial-with-no-new-Safety-Observations.html

    GLOBENEWSWIRE
    02 Oct 2025
    Share Share
    Nicox to Repay Debts Fully with NCX 470 Global Licensing
    Nicox to Repay Debts Fully with NCX 470 Global Licensing

    04 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/04/3144181/0/en/Nicox-Expects-to-Fully-Repay-Financial-Debts-with-NCX-470-De-Risked-and-Globally-Licensed.html

    GLOBENEWSWIRE
    04 Sep 2025
    Share Share
    Nicox Announces Shareholder Q&A Webpage Available
    Nicox Announces Shareholder Q&A Webpage Available

    26 Aug 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/08/26/3138966/0/en/Nicox-Announces-Shareholder-Q-A-Webpage-Available.html

    GLOBENEWSWIRE
    26 Aug 2025
    Share Share
    Nicox Reports Positive NCX470 Ph 3 Trial Results in Glaucoma
    Nicox Reports Positive NCX470 Ph 3 Trial Results in Glaucoma

    21 Aug 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/08/21/3136836/0/en/Nicox-Announces-Positive-Results-from-the-NCX-470-Phase-3-Denali-Trial-in-Glaucoma-Patients.html

    GLOBENEWSWIRE
    21 Aug 2025
    Share Share
    Nicox Expands Flexible Equity Financing
    Nicox Expands Flexible Equity Financing

    08 Aug 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/08/08/3129916/0/en/Nicox-Extends-Existing-Flexible-Equity-Financing.html

    GLOBENEWSWIRE
    08 Aug 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search